Altimmune, Inc. Aktie News

Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows:

Altimmune, Inc. ( ALT ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:00 AM EST Company Participants Vipin Garg - President, CEO & Director Christophe Arbet-Engels - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division All right. Good morning, everyone, to Jefferies' London Hea...

Altimmune remains a speculative buy as pemvidutide shows strong Phase IIb MASH results, confirmed by a recent Lancet publication. ALT's pemvidutide demonstrates significant MASH resolution, fibrosis improvement, and favorable safety, differentiating it from competitors and supporting a bullish long-term outlook. Risks include upcoming 48-week binary data, regulatory uncertainty, financial dilut...

24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc.  (Nasdaq: ALT), a late clinical-stage bi...

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement

Altimmune, Inc. ( ALT ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Vipin Garg - President, CEO & Director Linda Richardson - Chief Commercial Officer Gregory Weaver - Chief Financial Officer M. Roberts - Chief Scientific Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Patrick ...

48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer Cash, cash equivalents and short-term investments of $211 million as of September 30, 2025 Webcast to be...